ClinicalTrials.gg
CompletedNCT06255808Updated Oct 6, 2026

Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor

An observational study in Breast Cancer, Breast Neoplasm and Artificial Intelligence, sponsored by Seoul National University Hospital. Completed at 1 site in South Korea. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Seoul National University Hospital · Observational

How we know

Updated Oct 6, 2026Now CompletedFirst site in South Korea+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Breast Neoplasms by Seoul National University Hospital — 13 open to participants now, 21 under way, 3 of them phase 3. Breast Neoplasms · Seoul National University Hospital.

Enrollment
15th of 22
200 · median 352
Started
2022
with 7 others
Observational
22 of 50
5 open now
Registered
45th of 50
by date

Among the 50 studies in Breast Neoplasms by Seoul National University Hospital, this one is the 15th largest by enrollment of the 22 observational ones that give a count, is one of 8 that started in 2022, is one of 22 observational ones, and was the 45th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 50 studies in Breast Neoplasms by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Breast Neoplasms by Seoul National University Hospital, or all of them as a file.
02

Study summary

The accuracy of breast examinations and ultrasonography performed clinically to detect breast mass varies greatly depending on the physician\'s skill level, and the accuracy of breast examinations by non-experts is particularly low. In this study, we aimed to validate whether the concurrent use of ultrasound sensor technology is an efficient strategy for the purpose of improving the sensitivity of detecting breast masses through breast examination.

Read the detailed description

[Background] This research team would like to conduct this study based on the idea that the sensitivity of breast palpation can be improved by moving away from traditional breast palpation, which is simply performed by hand, and using auxiliary examination equipment based on ultrasonic sensor technology. In particular, our research team focused on the waveform of the ultrasound itself rather than the visual images obtained through the ultrasound device. In the existing breast ultrasound, the medical staff reads images created through ultrasound from multiple sensors to confirm the possibility of breast cancer, and this is read based on the medical staff\'s very subjective opinions. However, ultrasonic waveforms acquired through ultrasound can store information about the waveform as data and thus be implemented as objective values.

[Study design] Prospective, multi-institutional

[Study protocol]

① Preoperative ultrasound sensor-based diagnostic equipment was applied to 200 patients with breast mass among patients admitted to the breast surgery department, and prospectively obtained ultrasound echo signal data generated by the mass.

② For this purpose, the researcher uses equipment containing a single ultrasound sensor to manually scan the mass lesion area and no evidence disease area.

③ Diagnostic performance (judgment for presence or absence of a tumor) of diagnostic tool based on ultrasound sensor technology through an artificial intelligence algorithm designed based on ultrasound wavelength and frequency optimized for mass detection.

[Objectives]

  1. Primary endpoint Sensitivity/specificity/predictive value/accuracy/positive \& negative predictive of diagnostic performance
  2. Secondary endpoint Artificial intelligence algorithm efficacy
03

Conditions studied

  • Breast Cancer
  • Breast Neoplasm
  • Artificial Intelligence
  • Ultrasonography
  • Benign Breast Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

scheduled for surgery after a tumor has been confirmed on breast ultrasound examination

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients between 18 and 80 years of age who are scheduled for surgery after a tumor has been confirmed on breast ultrasound examination

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with breast cancer after with non-mass enhancement or calcification
  • Inflammatory breast cancer
  • Patients whose cancer has invaded the skin and broken through
  • Patients with skin diseases
  • Women who refused to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (actual)
Patient registry
No

Groups and cohorts

  • Ultrasonic group
06

What researchers measure

Primary outcomes

  1. Device performance

    Sensitivity/specificity/predictive value/accuracy/positive predictive value/ negative predictive value of diagnostic performance

    Time frame: Within 1 year after the study participant registration deadline

Secondary outcomes

  1. Artificial intelligence algorithm efficacy

    Time frame: Within 2 year after the study participant registration deadline

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Seoul 03080, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jan 2024, 15 months.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 15 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: start Oct 2024 → Oct 2022, primary completion Feb 2025 → Jan 2024 and completion Apr 2025 → Jan 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2024
First posted
Feb 13, 2024
StartActual
Oct 5, 2022was Oct 2024
Primary completionActual
Jan 5, 2024was Feb 2025
CompletionActual
Jan 5, 2025was Apr 2025
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 6, 2026
Sites
1 site added, 1 site removed — first site in South Korea; no longer in Korea, Republic of
Show site
  • Seoul National University Hospital · Seoul, South Korea
Show 1 removed
  • Seoul National University Hospital · Seoul, Korea, Republic of
Oct 6, 2026
Start date
Oct 5, 2024→Oct 5, 2022
Oct 6, 2026
Primary completion
Feb 27, 2025→Jan 5, 2024 (actual)
Oct 6, 2026
Study completion
Apr 5, 2025→Jan 5, 2025 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Active, not recruiting→Completed
    1 site added, 1 site removed — first site in South Korea; no longer in Korea, Republic of
    Show site
    • Seoul National University Hospital · Seoul, South Korea
    Show 1 removed
    • Seoul National University Hospital · Seoul, Korea, Republic of
    Start date Oct 5, 2024→Oct 5, 2022
    Primary completion Feb 27, 2025→Jan 5, 2024 (now actual)
    Study completion Apr 5, 2025→Jan 5, 2025 (now actual)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06255808
Responsible party
Hyeong-Gon Moon (Professior, Seoul National University Hospital) — Principal investigator
First posted
Feb 13, 2024
Start date
Oct 5, 2022
Primary completion
Jan 5, 2024
Completion
Jan 5, 2025
Last update
Oct 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion